Bone Therapeutics to build new manufacturing facility in Belgium
The new manufacturing facility, which is funded through equity and loans basis from ING and BNP Paribas Fortis and subsidies from the Walloon Region, will produce its unique
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Currently, this work is focused on developing and validating new ways for quick forensic screening and analysis based on advanced chromatography and mass-spectrometry systems such as LC-QQQ-MS/MS, LC-QTOF-MS,